You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 62 No. 11, November 2005 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on ISI (13)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Alzheimer Disease
 •Cerebrovascular Disease
 •Alert me on articles by topic

Circulating Levels of Soluble Receptor for Advanced Glycation End Products in Alzheimer Disease and Vascular Dementia

Enzo Emanuele, MD; Angela D’Angelo, PhD; Carmine Tomaino, PhD; Giuliano Binetti, MD; Roberta Ghidoni, PhD; Pierluigi Politi, MD; Livia Bernardi, PhD; Raffaele Maletta, MD; Amalia C. Bruni, MD; Diego Geroldi, MD

Arch Neurol. 2005;62:1734-1736.

Background  The receptor for advanced glycation end products (RAGE) is a cell surface receptor that has been implicated in vascular disease and neurodegeneration. Low levels of its secreted isoform, soluble RAGE (sRAGE), have been regarded as a putative risk factor for atherosclerosis. In addition, administration of sRAGE has been shown to reduce development of cerebral {beta}-amyloidosis in an Alzheimer disease mouse model.

Objective  To investigate the role of sRAGE as a biological marker for Alzheimer disease and vascular dementia.

Design  Cross-sectional study of 152 patients with a clinical diagnosis of Alzheimer disease, 91 with vascular dementia and 161 control subjects.

Main Outcome Measure  Plasma levels of sRAGE.

Results  Levels of sRAGE were significantly reduced in the plasma of patients with Alzheimer disease compared with that for those with either vascular dementia (P<.05) or with controls (P<.001).

Conclusions  Patients with Alzheimer disease have reduced levels of sRAGE in plasma compared with patients with vascular dementia and controls. The striking reduction of circulating sRAGE in Alzheimer disease further supports a role for the RAGE axis in this clinical entity and requires further investigation.


Author Affiliations: Molecular Medicine Laboratory (Dr Emanuele), Department of Internal Medicine and Medical Therapeutics (Drs Geroldi and D’Angelo), and Department of Psychiatry (Dr Politi), University of Pavia, IRCCS San Matteo Hospital, Pavia, Italy; Regional Neurogenetic Centre AS6, Lamezia Terme, Italy (Drs Tomaino, Bernardi, Maletta, and Bruni); Memory Clinic, NeuroBioLab, IRCCS Centro San Giovanni di Dio, Fatebenefratelli, Brescia, Italy (Drs Binetti and Ghidoni).







HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.